HomeQuestion

Does the 5-year OS data influence which patients with high-risk NMIBC you are selecting for durvalumab plus BCG (POTOMAC) over BCG monotherapy alone?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?

How do the results of KEYNOTE-B15/EV-304 influence your preferred treatment for cisplatin eligible MIBC?

How does the POSEIDON meta-analysis results influence your decision on which patients should receive hormone therapy with post-operative radiotherapy for recurrent prostate cancer?

Is the PROTEUS data enough to change your practice in the treatment of patients with high-risk localized or locally advanced prostate cancer?

Can you extrapolate the PROTEUS data and replace apalutamide with other ARPIs for high-risk localized or locally advanced prostate cancer if approved?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.